DigiM Solution

DigiM Solution is a microstructure science company headquartered in Woburn, Massachusetts, founded in 2014 by Dr. Shawn Zhang. The company applies 3D imaging, AI-driven image analysis, and physics-based simulation to digitize the internal structure of drug products — creating what it calls "digital twins" of formulations — so that pharmaceutical developers can predict product quality and performance before running bench experiments. Its stated mission is to deliver advanced 3D microstructure intelligence that predicts product quality and performance, accelerates pharmaceutical development, and de-risks regulatory approval. The firm's core methodology is Image-to-Simulation, or I2S, an end-to-end workflow that moves through four sequential stages: imaging, analysis, quantification, and prediction. In the imaging stage, correlative microscopy — including FIB-SEM, X-ray microCT, and optical microscopy — captures drug product structure across length scales, from nanometer-scale active pharmaceutical ingredient (API) particles to whole-tablet architecture. In the analysis stage, deep learning segmentation models trained on pharmaceutical microstructures automatically separate API, excipient, polymer, and pore phases. Quantification then converts these into measurable microstructure attributes, and prediction uses microstructure-faithful models, mechanistic simulation, and generative AI structure synthesis to digitally optimize formulation and process. DigiM serves pharmaceutical innovators and generic developers across nearly all dosage forms and therapeutic modalities, including long-acting injectables, lyophilization, oral products, implants, nanocarriers, and topicals. The company reports having supported more than 189 drug programs, digitized over 1,516 formulations, and worked with more than 68 pharmaceutical partners, including many of the world's largest innovators and generic developers. Its engagements span innovator NDAs, generic ANDAs, and regulatory consulting. A distinguishing element of DigiM's business is its work with regulatory agencies. The company states that its team partners with regulators to develop regulatory guidelines, validate scientific methodology, and support regulatory science research through grants and software subscriptions, and that it supports clients across all filing types and stages. Its cloud-based image processing platform, digiM I2S, is designed to manage the complete lifecycle of image data; the company has noted that an FDA guideline cites digiM I2S software in connection with ophthalmic implants. DigiM is a privately held company. Its leadership team includes co-founder and Managing Director Dr. Shawn Zhang, who holds a Ph.D. in Computational Physics from Rutgers University and previously held senior positions at CAE software company Fluent (now Ansys) and electron microscopy company FEI (now Thermo Fisher). Other leaders include Dr. Andrew Clark, Senior Director of Research and Strategy, and Dr. Aiden Zhu, Director of Imaging Science.

DigiM Solution was founded in 2014 by Dr. Shawn Zhang and is headquartered in Woburn, Massachusetts. Zhang, who serves as co-founder and Managing Director, holds a Ph.D. in Computational Physics from Rutgers University with a minor in Computer Engineering. Before founding the Boston-area company, he held senior positions at the CAE software company Fluent (now part of Ansys) and at the electron microscopy company FEI (now part of Thermo Fisher). That combination of computational simulation and imaging experience shaped DigiM's founding premise: that the internal microstructure of a drug product — the spatial arrangement of API particles, excipients, polymers, and pores — governs how the product performs, and that this structure can be captured, digitized, and simulated. From its founding, the company built its business around what it calls Image-to-Simulation, or I2S, an end-to-end workflow with four sequential stages. The first stage, imaging, uses correlative microscopy — FIB-SEM, X-ray microCT, and optical microscopy — to capture drug product structure across every length scale, from nanometer API particles to whole-tablet architecture in a single study. The second stage, analysis, applies deep learning segmentation models trained on pharmaceutical microstructures to automatically separate API, excipient, polymer, and pore phases, turning raw image data into structured analytical inputs. The third stage, quantification, converts these into measurable microstructure attributes that can be linked to critical quality attributes (CQAs) and critical process parameters (CPPs). The fourth stage, prediction, uses microstructure-faithful models, mechanistic simulation, and generative AI structure synthesis to digitally optimize formulation and process, reducing the number of physical experiments required. Over its first decade, DigiM applied this methodology across nearly all major dosage forms and therapeutic modalities, including long-acting injectables, lyophilization, oral products, implants, nanocarriers, and topicals. The company reports that since 2014 it has digitized more than 1,516 formulations, supported more than 189 drug programs spanning innovator NDAs, generic ANDAs, and regulatory consulting engagements, and worked with more than 68 pharmaceutical partners, including many of the world's largest innovators and generic developers. A distinctive thread in DigiM's history is its engagement with regulators. The company states that its team partners with regulatory agencies to develop regulatory guidelines, validate scientific methodology, and support regulatory science research through grants and software subscriptions, and that it supports clients in all filing types and stages. Its cloud-based image processing platform, digiM I2S, is designed to manage the complete lifecycle of image data; the company has highlighted that an FDA guideline cites digiM I2S software in connection with ophthalmic implants. DigiM remains a privately held company. Its leadership team has grown to include Dr. Andrew Clark, Senior Director of Research and Strategy, who leads a team of application scientists and holds a Ph.D. in Physics from Tufts focused on experimental polymer physics and solid-state characterization; Dr. Aiden Zhu, Director of Imaging Science, who brought more than 15 years of pharmaceutical industry experience, including managing imaging labs at Mass General Hospital and Pfizer; and Dr. Ronald Smith, Executive Advisor.

• 2014

  DigiM Solution founded by Dr. Shawn Zhang; headquartered in Woburn, Massachusetts.

• Company develops and commercializes its Image-to-Simulation (I2S) workflow combining correlative microscopy, AI image analytics, and physics-based simulation.

• digiM I2S cloud-based image processing platform launched to manage the complete lifecycle of image data.

• FDA guideline cites digiM I2S software in connection with ophthalmic implants.

• Company reports more than 1,516 formulations digitized, 189+ drug programs supported, and 68+ pharmaceutical partners.

A specialized pharmaceutical microstructure science provider combining 3D imaging, AI analytics, and physics-based simulation to de-risk drug development and regulatory approval.

• Microstructure Imaging

  Correlative microscopy (FIB-SEM, X-ray microCT, optical microscopy) creating permanent, reusable digital twins of drug product microstructure.

• Microstructure Quantification

  Proprietary AI image analysis and automation that quantifies microstructure attributes as strategic quality levers, enhancing CQAs and linking to CPPs.

• Microstructure Performance Prediction

  Microstructure-faithful predictions using real-world 3D structures, mechanistic models, and generative AI structure synthesis to digitally optimize formulation and process.

• digiM I2S

  Cloud-based image processing platform (Image-to-Simulation) designed to manage the complete lifecycle of image data.

1. 1digiM Solution - Microstructure Science for Drug Developmentdigimsolution.com
2. 2About DigiM Solution - Microstructure Science for Pharmadigimsolution.com
3. 3Team - DigiM Solutiondigimsolution.com
4. 4News - DigiM Solutiondigimsolution.com
5. 5DigiM Solution - Wikidatawikidata.org